Sanochemia/SPL: Investigational Iron-Based MRI Contrast Agent Meets Primary Endpoints in Pivotal Phase III Study
Neufeld, Austria, February 25th, 2025 – Sanochemia Pharmazeutika today announced positive headline results of the…
Read moreWith the development, production and distribution of pharmaceutical specialties, we have been contributing to people’s health for more than 30 years. Our strengths include the development and manufacture of sterile liquid dosage forms and small molecule active pharmaceutical ingredients. For our own needs and as CDMO for third parties.
In Austria, we develop, produce and distribute some of the most established generic imaging agents under the Sanochemia brand. Our products help physicians make efficient therapeutic decisions for patients.
With contract manufacturing of sterile and low-bioburden liquids as well as APIs, we offer in-depth expertise in the field of drug product and API production. As a full-service provider, we also support with GMP services.
Neufeld, Austria, February 25th, 2025 – Sanochemia Pharmazeutika today announced positive headline results of the…
Read moreSanochemia Pharmazeutika continues to strengthen its position in medical imaging with the submission of an application for its liver-specific contrast agent in multiple European countries.
Read moreThe registration initiative launched by Sanochemia Pharmazeutika in 2021, together with the continuously increasing market demand, has led to a record volume of orders.
Read more